Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR)

Research output: Contribution to journalArticle

Standard

Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden : a report from the Swedish Coronary and Angioplasty Registry (SCAAR). / Buccheri, Sergio; James, Stefan; Lindholm, Daniel; Fröbert, Ole; Olivecrona, Göran K.; Persson, Jonas; Hambraeus, Kristina; Witt, Nils; Erlinge, David; Angerås, Oskar; Lagerqvist, Bo; Sarno, Giovanna.

In: European Heart Journal, Vol. 40, No. 31, 14.08.2019, p. 2607-2615.

Research output: Contribution to journalArticle

Harvard

Buccheri, S, James, S, Lindholm, D, Fröbert, O, Olivecrona, GK, Persson, J, Hambraeus, K, Witt, N, Erlinge, D, Angerås, O, Lagerqvist, B & Sarno, G 2019, 'Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR)', European Heart Journal, vol. 40, no. 31, pp. 2607-2615. https://doi.org/10.1093/eurheartj/ehz244

APA

CBE

MLA

Vancouver

Author

Buccheri, Sergio ; James, Stefan ; Lindholm, Daniel ; Fröbert, Ole ; Olivecrona, Göran K. ; Persson, Jonas ; Hambraeus, Kristina ; Witt, Nils ; Erlinge, David ; Angerås, Oskar ; Lagerqvist, Bo ; Sarno, Giovanna. / Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden : a report from the Swedish Coronary and Angioplasty Registry (SCAAR). In: European Heart Journal. 2019 ; Vol. 40, No. 31. pp. 2607-2615.

RIS

TY - JOUR

T1 - Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden

T2 - a report from the Swedish Coronary and Angioplasty Registry (SCAAR)

AU - Buccheri, Sergio

AU - James, Stefan

AU - Lindholm, Daniel

AU - Fröbert, Ole

AU - Olivecrona, Göran K.

AU - Persson, Jonas

AU - Hambraeus, Kristina

AU - Witt, Nils

AU - Erlinge, David

AU - Angerås, Oskar

AU - Lagerqvist, Bo

AU - Sarno, Giovanna

PY - 2019/8/14

Y1 - 2019/8/14

N2 - Aims: Randomized clinical trials have consistently demonstrated the non-inferiority of bioabsorbable polymer drug-eluting stents (BP-DES) with respect to DES having permanent polymers (PP-DES). To date, the comparative performance of BP- and PP-DES in the real world has not been extensively investigated. Methods and results: From October 2011 to June 2016, we analysed the outcomes associated with newer generation DES use in Sweden. After stratification according to the type of DES received at the index procedure, a total of 16 504 and 79 106 stents were included in the BP- and PP-DES groups, respectively. The Kaplan-Meier estimates for restenosis at 2 years were 1.2% and 1.4% in BP- and PP-DES groups, respectively. Definite stent thrombosis (ST) was low in both groups (0.5% and 0.7% in BP- and PP-DES groups, respectively). The adjusted hazard ratio (HR) for either restenosis or definite ST did not differ between BP- and PP-DES [adjusted HR 0.95, 95% confidence interval (CI) 0.74-1.21; P = 0.670 and adjusted HR 0.79, 95% CI 0.57-1.09; P = 0.151, respectively]. Similarly, there were no differences in the adjusted risk of all-cause death and myocardial infarction (MI) between the two groups (adjusted HR for all-cause death 1.01, 95% CI 0.82-1.25; P = 0.918 and adjusted HR for MI 1.05, 95% CI 0.93-1.19; P = 0.404). Conclusion: In a large, nationwide, and unselected cohort of patients, percutaneous coronary intervention with BP-DES implantation was not associated with an incremental clinical benefit over PP-DES use at 2 years follow-up.

AB - Aims: Randomized clinical trials have consistently demonstrated the non-inferiority of bioabsorbable polymer drug-eluting stents (BP-DES) with respect to DES having permanent polymers (PP-DES). To date, the comparative performance of BP- and PP-DES in the real world has not been extensively investigated. Methods and results: From October 2011 to June 2016, we analysed the outcomes associated with newer generation DES use in Sweden. After stratification according to the type of DES received at the index procedure, a total of 16 504 and 79 106 stents were included in the BP- and PP-DES groups, respectively. The Kaplan-Meier estimates for restenosis at 2 years were 1.2% and 1.4% in BP- and PP-DES groups, respectively. Definite stent thrombosis (ST) was low in both groups (0.5% and 0.7% in BP- and PP-DES groups, respectively). The adjusted hazard ratio (HR) for either restenosis or definite ST did not differ between BP- and PP-DES [adjusted HR 0.95, 95% confidence interval (CI) 0.74-1.21; P = 0.670 and adjusted HR 0.79, 95% CI 0.57-1.09; P = 0.151, respectively]. Similarly, there were no differences in the adjusted risk of all-cause death and myocardial infarction (MI) between the two groups (adjusted HR for all-cause death 1.01, 95% CI 0.82-1.25; P = 0.918 and adjusted HR for MI 1.05, 95% CI 0.93-1.19; P = 0.404). Conclusion: In a large, nationwide, and unselected cohort of patients, percutaneous coronary intervention with BP-DES implantation was not associated with an incremental clinical benefit over PP-DES use at 2 years follow-up.

KW - Bioabsorbable polymer

KW - Clinical outcomes

KW - Drug-eluting stents

KW - Permanent polymer

KW - Stent failure

U2 - 10.1093/eurheartj/ehz244

DO - 10.1093/eurheartj/ehz244

M3 - Article

VL - 40

SP - 2607

EP - 2615

JO - European Heart Journal

JF - European Heart Journal

SN - 1522-9645

IS - 31

ER -